FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease Published: Oct. 26, 2020 By Mark Terry BioSpace FibroGen presented data from two pooled analyses from its roxadustat global Phase III development program this weekend at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined conference. The analyses looked at associations between the […]
The U.S. Food and Drug Administration approved AstraZeneca Plc’ drug for reducing the risk of a first heart attack or stroke in high-risk patients with coronary artery disease.
Researchers developed a type of nanoparticle that can “eat debris” related to the plaques that cause heart attacks.
Novo Nordisk’s Ozempic (semaglutide) won approval from the U.S. Food and Drug Administration to reduce the risk of major adverse cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and known heart disease.
One week after announcing positive data from ORION-10, the second of three 19-month Phase III trials for inclisiran for lowering cholesterol, The Medicines Co. was acquired by Novartis.
Swiss company Vifor Pharma and Germany’s Evotec AG launched a joint venture to focus on the discovery and development of new therapies for kidney diseases.
The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals’ cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.
Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto.
The number of push-ups a man can do in the doctor’s office may be a good predictor of his risk of developing heart disease in the coming years, new research suggests.